2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-128345
    UDM-001651 1477497-01-0 98%
    UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM). UDM-001651 shows antiplatelet potency (IC50=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP).
    UDM-001651
  • HY-128511
    Piridoxilate 24340-35-0 98%
    Piridoxilate (Piridoxylate), a glyoxylate derivative, is an anti-anoxic agent. Piridoxilate can be used in research on vascular diseases and coronary occlusion.
    Piridoxilate
  • HY-128546
    Flupranone 21686-10-2 98%
    Flupranone is a pyrazole derivatives with antiinflammatory and antihypertensive properties.
    Flupranone
  • HY-128561
    AM12 2387510-84-9 98%
    AM12 inhibits Lanthanide-evoked TRPC5 activity with an IC50 of 0.28 μM.
    AM12
  • HY-129088
    HUP30 312747-21-0 99.68%
    HUP30 is a vasodilating agent. HUP30 stimulates soluble guanylyl cyclase, activate K+ channels, and blocks extracellular Ca2+ influx.
    HUP30
  • HY-129199
    U-51605 64192-56-9 98%
    U-51605 is a platelet aggregation inhibitor and inhibits thromboxane synthesis. U-51605 is also a prostaglandin I2 synthase inhibitor and can inhibit the retinal vasodilation response induced by NO donors (such as NOR3).
    U-51605
  • HY-129210
    KMUP-4 864873-81-4 98%
    KMUP-4, as a xanthine derivative with cGMP-enhancing activity, induces aortic relaxation through endothelium-dependent and independent mechanisms. KMUP-4 increases cytoplasmic cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) levels by inhibiting phosphodiesterases (PDEs) and activating K+ channels. KMUP-4 can be used in the study of cardiovascular diseases.
    KMUP-4
  • HY-129213
    CL-242817 86709-48-0 98%
    CL-242817 is an orally available angiotensin converting enzyme (ACE) inhibitor. CL-242817 inhibits the conversion of angiotensin I to angiotensin II and has blood pressure lowering activity. CL-242817 can also improve Monocrotaline (HY-N0750) induced lung injury. CL-242817 can be used in the study of pulmonary fibrosis and hypertension-related diseases.
    CL-242817
  • HY-129230
    Triletide 62087-96-1 98%
    Triletide is a thromboxane A2 antagonist with good oral absorption activity. The biotransformation of Triletide mainly includes the formation of demethyl, deacetyl, demethyl-deacetyl and hydroxy derivatives. The distribution half-life of Triletide is about 1 hour, and the elimination half-life is about 5 hours.
    Triletide
  • HY-129244
    Levamlodipine (gentisate) 856256-16-1 98%
    Levamlodipine gentisate ((S)-Amlodipine gentisate) is a pharmacologically active amino ester with calcium channel blocker activity. Levamlodipine gentisate is used as an antihypertensive and antianginal compound. The enantiomeric purity of levamlodipine gentisate can be determined by a fast capillary electrophoresis method. The highest resolution of levamlodipine gentisate reached 9.8, indicating its potential application in compound analysis.
    Levamlodipine (gentisate)
  • HY-129278
    Lunarine 24185-51-1 98%
    Lunarine is an alkaloid, which can be isolated from the seeds of kale (Lunaria annua). Lunarine lowers the blood pressure, stimulates small intestinal motility, inhibits spontaneous contractions of uterus and nervous system, and exhibits an acute toxicity with LD50 of 62.3 mg/kg in dogs and rabbits. Lunarine exhibits antiparasitic activity through a competitive inhibition of protozoan oxidoreductase trypanothione reductase (TryR) with Ki of 304 μM.
    Lunarine
  • HY-129340
    AS-183 147317-12-2 98%
    AS-183 is an inhibitor of cholesterol acyltransferase (ACAT) (IC50=0.94 µM). AS-183 also inhibits the formation of cholesterol esters in HepG2, CaCo2 and THP-1 cells with IC50 values ​​of 18.1, 25.5 and 34.5 µM, respectively. AS-183 can be used in the study of atherosclerosis and hypercholesterolemia.
    AS-183
  • HY-129406
    AF 698 82958-11-0 98%
    AF 698 is a phthalate derivative of Apovincamine (HY-135743) that can be used as a peripheral vasodilator with selective vasomotor effects on cerebral microvascular circulation. AF 698 has better vasodilator effect than Vincamine (HY-B1021), but there is no significant difference in the protective effect of the two drugs against hypobaric hypoxia-induced lethality in mice.
    AF 698
  • HY-129412
    A-74273 130316-95-9 98%
    A-74273 is an orally active peptide renin inhibitor (IC50=3.1 nM). A-74273 competitively binds to the active site of renin, preventing angiotensinogen from being converted to ANG-I, thereby reducing the level of angiotensin II. A-74273 can be used in the study of diseases such as hypertension.
    A-74273
  • HY-129436
    (S)-Bucindolol 91548-61-7 98%
    (S)-Bucindolol is the (S)-isomer of Bucindolol (HY-103214), a β1-adrenergic receptor blocker. (S)-Bucindolol can be utilized in research on cardiac failure.
    (S)-Bucindolol
  • HY-129458
    Cerivastatin 145599-86-6 98%
    Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect.
    Cerivastatin
  • HY-129500
    Zofenoprilat arginine 81872-09-5 98%
    Zofenoprilat arginine is an antihypertensive agent that enhances the effect of bradykinin on coronary flow, particularly in the presence of sulfhydryl-containing converting enzyme inhibitors.
    Zofenoprilat arginine
  • HY-129660
    LK 204-545 83068-69-3 98%
    LK 204-545 is a potent and highly selective β1-adrenoceptor antagonist. LK 204-545 is promising for research of cardiovascular diseases.
    LK 204-545
  • HY-129670
    KMUP-1 81996-46-5
    KMUP-1 is a xanthine derivative with vasodilator activity. KMUP-1 is a inhibitor of phosphodiesterase (PDE) and activator of soluble guanylyl cyclase (sGC). KMUP-1 stimulates NO/sGC/cyclic GMP pathway. KMUP-1 has K+ channels opening activity. KMUP-1 ameliorates ischemia-induced cardiomyocyte apoptosis. KMUP-1 can be used for cardiovascular and anti-inflammatory study.
    KMUP-1
  • HY-129695
    PD 132002 134452-04-3 98%
    PD 132002 is an orally active, potent renin inhibitor. PD 132002 weakly inhibits pepsin. PD 132002 produces substantial reductions in blood pressure.
    PD 132002
Cat. No. Product Name / Synonyms Application Reactivity